CML publications

Please find below a selection of interesting articles on CML from peer-reviewed journals. Recent publications include:
Clinical papers

Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia
Efficace F et al. Cancer, October 2023 (epub ahead of print)
Spontaneous remission in a patient with chronic myeloid leukemia: A Case Report
Alshurufa A et al. Case Rep Oncol, October 2023 – open access publication
Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results
Gener-Ricos C et al. Clin Lymphoma Myeloma Leuk, October 2023
Revisiting six established practices in the treatment of chronic myeloid leukemia - Review
Kantarjian HM et al. Lancet Haematol, October 2023
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy
Khadadah FM et al. Leuk Res, October 2023
Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions
Larfors G et al. Eur J Haematol, October 2023 – open access publication
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
Cross NCP et al. Leukemia, November 2023 – open access publication
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO Study
Zambrotta GPM et al. Am J Hematol, November 2023 – open access publication
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia:
Results from the phase 4 BYOND study
Rosti G et al. Leukemia, November 2023 (epub ahead of print) – open access publication
What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia?
Kantarjian HM Leukemia, November 2023
The new systematic coronary risk evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib and ponatinib
Mulas O et al. Ann Hematol, November 2023
Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor
Park H et al. Ther Adv Hematol, November 2023 – open access publication
Frequency and prognostic influence of ASXL1 mutations and its potential association with BCR-ABL1 transcript type and smoke in chronic myeloid leukemia patients
Rafiq Mohammed A et al. Gene, November 2023

Scientific papers

Deciphering potential molecular signatures to differentiate acute myeloid leukemia (AML) with BCR::ABL1 from chronic myeloid leukemia (CML) in blast crisis
Boucher L et al. Int J Mol, October 2023 – open access publication
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation
Huuhtanen J et al. Leukemia, November 2023 (epub ahead of print) – open access publication

More CML Publications 2023

Clinical Publications	Scientific Publications
November 2023
	Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia Shin JE et al. Mol Cancer, November 2023 – open access publication
	Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment Häselbarth L et al. BMC Cancer, November 2023 – open access publication
October 2023
Viral infections and incidence of reactivation in chronic myeloid leukemia patients – Review Aldapt MB et al. Oncology, October 2023 (epub ahead of print)	Transporter-mediated cellular distribution of tyrosine kinase inhibitors as a potential resistance mechanism in chronic myeloid leukemia - Review Verhagen NE et al. Pharmaceutics, October 2023 – open access publication
Comparative efficacy and safety of different doses of ponatinib versus other tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia: a systematic review and network analysis – Review Zhang S et al. Expert Opin Drug Saf, October 2023 (epub ahead of print)	Mitochondrial complex I inhibition by homoharringtonine: A novel strategy for suppression of chronic myeloid leukemia Han H et al. Biochem Pharmacol, October 2023 (epub ahead of print)
	A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells Zhang X et al. Cell Mol Biol Lett, October 2023 – open access publication
	AZD-7648, a DNA-PK inhibitor, induces DNA damage, apoptosis, and cell cycle arrest in chronic and acute myeloid leukemia cells Lapa BS et al. Int J Mol, October 2023 – open access publication
September 2023
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib Kok CH et al. Blood Cancer J, Sept 2023 (epub ahead of print) – open access publication	Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention Shanmunagathan N et al. Haematologica, Sept 2023 – open access publication
Survival with chronic myeloid leukemia after failing milestones Lauseker M et al. Leukemia, September 2023 (epub ahead of print) – open access publication	New patterns of genetic instability in chronic myeloid leukemia: Interesting, but not ready for clinical use Schiffer CA. Haematologica, Sept 2023 – open access publication
Treatment-free remission after dasatinib in patients with chronic myeloid leukemia in chronic-phase with deep molecular response: Final 5-year analysis of DASFREE Shah NP et al. Br J Haematol, Sept 2023 - open access publication	Aquired miR-142 deficit in leukemia stem cells suffices to drive chronic myeloid leukemia into blast crisis Zhang B et al. Nat Commun, Sept 2023 – open access publication
The (near) miracle of therapy in chronic myeloid leukemia Radich JP. Br J Haematol, Sept 2023 – open access publication	Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells Okabe S and Gotoh A. BMC Cancer, Sept 2023
Improvement, implementation, and evaluation of the CMyLife Digital Care Platform: Participatory Action Research Approach Verweij L et al. J Med Internet Res, Sept 2023 - open access publication	The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on TKI therapy predicts the imatinib treatment failure Ratajczak B et al. Leuk Res, Sept 2023 – open access publication
BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population Kockerols C et al. Eur J Haematol, Sept 2023 (epub ahead of print)	MicroRNA based combinatorial therapy against TKIs resistant CML by inactivating the PI3K/Akt/mTOR pathway: a review Sing P. Med Oncol, Sept 2023
External validation of the predictive scoring systems for molecular responses in chronic myeloid leukemia receiving initial imatinib therapy Qi F et al. Leukemia, Sept 2023
Final report of TKI discontinuation trial with dasatinib for the second attempts of treatment-free remission after failing the first attempts with imatinb: Treatment-free Remission Accomplished by Dasatinib (TRAD) Study Perusini MA et al. Br J Haematol, Sept 2023 (epub ahead of print)
Risk factors determining adherence to tyrosine kinase inhibitors in chronic myeloid leukemia Del Rosario García B et al. J Oncol Pharm Pract, Sept 2023 (epub ahead of print)
The expanding CML treatment landscape: an introspective commentary Lipton JH, Blood Cancer J, Sept 2023 (epub ahead of print) – open access publication
Bilateral massive retinal infiltrates: Sign of blast crisis in chronic myeloid leukemia Patel A et al. Ophthalmology, Sept 2023 (epub ahead of print)
Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice Ielo C et al. Leuk Lymphoma, Sept 2023 (epub ahead of print)
Case Report: ASXL1, RUNX1, and IDH1 mutation in tyrosine kinase-independent resistant chronic myeloid leukemia progressing to chronic myelomonocytic leukemia-like accelerated phase Oyogoa E et al. Front Oncol, Sept 2023 – open access publication
August 2023
Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies Bhattacharjee U et al. Leuk Res, August 2023 (epub ahead of print)	Using natural killer cell-derived exosomes as a cell-free therapy for leukemia Samara A et al. Hematol Oncol, August 2023
One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission Laganà A et al. Eur J Haematol, August 2023 (epub ahead of print)	NDRG3 regulates imatinib resistance by promoting ß-catenin accumulation in the nucleus in chronic myelogenous leukemia Wang X et al. Oncol Rep, August 2023 – open access publication
Association of nilotinib with cardiovascular diseases in patients with chronic myelogenous leukemia: A National PopulationBased Cohort Study Huang CE et al. Oncologist, August 2023 (epub ahead of print) – open access publication	Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia Martínez-Castillo M et al. Leuk Res, August 2023
Measuring chronic myeloid leukemia TKI-related toxic effects in the real-world: a systematic review and critical assessment of content validity of patient-reported outcomes measures - Review Smit Y et al. Lancet Haematol, August 2023 (epub ahead of print)	Mitochondrial dysfunction in cardiotoxicity induced by BCR-ABL1 tyrosine kinase inhibitors – underlying mechanisms, detection, potential therapies – Review Sun S et al. Cardiovasc Toxicol, August 2023
Real-world experience with ponatinib therapy in chronic-phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events Abdelmagid MG et al. Blood Cancer J, August 2023 (epub ahead of print) – open access publication	Crizotinib acts as a ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL T315I and BCR-ABL1 T315I-E255KMian AA et al. Ann Hematol, August 2023 – open access publication
Reverse transcription can critically impact the diagnostic outcome of BCR::ABL1 quantitative real-time RT-PCR Spiess B et al. Cancers(Basel) – open access publication	MEK1/2 regulates normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia Mazzera L et al. Leukemia, August 2023 – open access publication
Interferon in chronic myeloid leukemia: Is it useful for treatment-free remission? Breccia M and Saglio G. Br J Haematol, August 2023 (epub ahead of print) – open access publication	High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors Aghel N et al. Leuk Lymphoma, August 2023 (epub ahead of print)
Step-in dosing of bosutinib in patients with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study Isfort S et al. Ann Hematol, August 2023 (epub ahead of print) – open access publication	Food for thought (and CML survival) Sezaki M and Huang G. Blood, August 2023
Population modelling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia Garret M et al. Cancer Med, August 2023 (epub ahead of print) – open access publication	Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells Rattigan KM et al. Nat Commun, August 2023 – open access publication
Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy Pagani IS et al. Blood, August 2023 (epub ahead of print)	The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associations with each resistance mechanisms Leow BCS et al. Sci Rep, Aug 2023 – open access publication
July 2023
Immune modulation in chronic myeloid leukemia patients treated with nilotinib and interferon-alpha Irani YD et al. Br J Haematol, July 2023 (epub ahead of print)	Genetic separation of chronic myeloid leukemia stem cells from normal hematopietic stem cells at single-cell resolution Chen Y et al. Leukemia, July 2023 – open access publication
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study Cortes JE et al. Haematologica, July 2023 (epub ahead of print) – open access publication	Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukemia stem cells Rattigan KM et al. EMBO Rep, July 2023 (epub ahead of print) – open access publication
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia Balsat M et al. Leuk Res, July 2023	Profiling of miRNAs and their interfering targets in peripheral blood mononuclear from patients with chronic myeloid leukemia Wu SC et al. Front Oncol, July 2023 – open access publication
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia Huguet F et al. Expert Rev Hematol, July 2023 (epub ahead of print)	Control of PH+ and additional chromosomal abnormalities in chronic myeloid leukemia by tyrosine kinase inhibitors Ansari S and Verma M. Med Oncol, July 2023
Quality-of-life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia Chen Y et al. Cancer Med, July 2023 (epub ahead of print) – open access publication	HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with chronic myeloid leukemia with the T315i mutation through the Akt-autophagy pathway Yin L et al. Hum Cell, July 2023
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era Haddad FG et al. Am J Hematol, July 2023 (epub ahead of print)	Phenotypic and functional characterization of subpopulation of imatinib resistant chronic myeloid leukemia cell line Hekmatshoar Y et al. Adv Med Sci, July 2023 (epub ahead of print)
Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia Braga AGO et al. Hematol Transfus Cell Ther, July 2023 (epub ahead of print) – open access publication	Histone demethylase PHF8 facilitates the development of chronic myeloid leukemia by directly targeting BCR::ABL1 Feng H et al. Br J Haematol, July 2023 (epub ahead of print) – open access publication
Real-world management of CML: outcomes and treatment patterns Held N and Atallah EL. Curr Hematol Malig Rep, July 2023 (epub ahead of print)
Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients Jacobi H et al. Front Pharmacol, July 2023 – open access publication
Fine-tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia: The choice of the right TKI for the right patient Nohoglu Kantarci E et al. Cancer, July 2023 (epub ahead of print)
June 2023
Impact of tyrosine kinase inhibitors applied for first-line chronic myeloid leukemia treatment on platelet function in whole blood of healthy volunteers in vitro Eckart F et al. Hamostaseologie, June 2023 – open access publication	Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis Radich JP et al. Haematologica, June 2023 – open access publication
Single cells tell multiple tales in CML Ross DM. Blood, June 2023 – open access publication	Project Confirm: Accelerated drug approvals for chronic myeloid leukemia Sweet KL et al. Clin Cancer Res, June 2023
Association of pre-treatment bone marrow morphology and achievement of BCR-ABL1 transcript milestone in CML Murkoviç M et al. Pathol Res Pract, June 2023	Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML Tribelli M et al. Cancer, June 2023 (epub ahead of print) – open access publication
BCR-ABL promotes hematopoietic stem and progenitor cell formation in embryonic stem cells Artus J et al. Exp Hematol, June 2023 (epub ahead of print)	Management of chronic myeloid leukemia patients in later lines: The role of ponatinib and new compounds - Review Scalzulli E et al. Clin Lymphoma Myeloma Leuk, June 2023
Using measurable residual disease to optimize management of AML, ALL, and chronic myeloid leukemia – Review Am Soc Clin Oncol Educ Book, June 2023 – open access publication	Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress Kantarjian HM and Tefferi A. Am J Hematol, June 2023 (epub ahead of print) – open access publication
Chronic myeloid leukemia during pregnancy with placental involvement: Case Report and Literature Review Çobankent Aytekin E et al. Fetal Pediatr Pathol, June 2023	Evaluation of physician guideline adherence and areas for improvement in managing patients with chronic myeloid leukemia: a cross-sectional survey Chen H et al. Leuk Lymphoma, June 2023 (epub ahead of print)
	Switching from imatinib to nilotinib plus pegylated interferon α2b in chronic phase chronic myeloid leukemia failing to achieve deep molecular response: clinical and immunologica effects Geelen IGP et al. Ann Hematol, June 2023
	Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulation surviving Yin SS et al. Cell Cycle, June 2023 – open access publication
	Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukemia cells Tsubaki M et al. Cell Prolif, June 2023 – open access publication
May 2023
Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery? Padala S and Cortes J. Haematologica, April 2023 (epub ahead of print) – open access publication	Modulating retinoid-x-receptor alpha RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo Rajmani BM et al. Front Pharmacol, May 2023 - open access publication
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal Pavlovsky C et al. J Hematol Oncol, April 2023 – open access publication	Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model Langhammer M et al. Leukemia, May 2023 (epub ahead of print) – open access publication
Cardiovascular risk in chronic myeloid leukemia: A multidisplinary consensus on screening and management Milojkovic D et al. Eur J Haematol, April 2023 (epub ahead of print) – open access publication	Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells Hiroshi H et al. Sci Rep, May 2023 – open access publication
Gene expression pattern of ESPL1, PTTG1 and PTTG1IP can potentially predict response to TKI first-line treatment of patients newly diagnosed CML Christiani E et al. Cancers(Basel), May 2023 – open access publication	Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells Qiu S et al. Blood, May 2023 (epub ahead of print)
A pragmatic approach to managing long-term adverse effects in chronic myeloid leukemia treatment - Review Lucero JA and Lipton JH. Curr Hematol Malig Rep, May 2023 (epub ahead of print)	Frequency and driver mutation diversity in concomitant chronic myeloid leukemia and Philadelphia chromosome-negative myeloproliferative neoplasm Langabeer SE et al. Int J Hematol, April 2023 (epub ahead of print)
The importance of developing open communication and a professional, long-term relationship between patients with chronic myeloid leukemia and their oncologist - Review Clements J et al. Future Oncol, May 2023 (epub ahead of print) – open access publication	Differentiation of imatinib-resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A. Xu Y et al. Cancer, May 2023 – open access publication
SOHO state of the art updates and next questions / Update on treatment-free-remission in chronic myeloid leukemia (CML) - Review Mikhaeel S and Atallah E. Clin Lymphoma Myeloma Leuk, May 2023	I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition Gao C et al. Front Pharmacol, April 2023 – open access publication
Imatinib compared to second-generation tyrosine kinase inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase Yang S et al. Am J Hematol, May 2023 (epub ahead of print) – open access publication	Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells Mitrovsky O et al. PLoSOne, May 2023 – open access publication
Response-based dosing for ponatinib: Model-based analyses of the dose-ranging OPTIC study Hanley MJ et al. Clin Pharmacol Ther, May 2023 (epub ahead of print)	Modeling global genomic instability in chronic myeloid leukemia (CML) using patient-derived induced pluripotent stem cells (iPSCs) Telliam G et al. Cancers(Basel), May 2023 – open access publication
Chronic Myeloid Leukemia following Exposure to Radioactive Iodine (I131): A Systematic Review Ali Hailan YM et al. Oncology, May 2023 – open access publication
A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia Kaddoura R et al. Front Med, May 2023 – open access publication
Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplant - Review Uhm J. Blood Res, April 2023 - open access publication
Developing therapeutic approaches for CML: a review Kumar V et al. Mol Cell Biochem, May 2023
The EMA assessment of Asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who were previously treated with at least two tyrosine kinase inhibitors Tesileanu CMS et al. Oncologist, May 2023 (epub ahead of print) – open access publication
Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase focusing on age and dose effects Tokuhira M et al. Int J Hematol, May 2023 (epub ahead of print)
Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted! Eskazan AE et al. Cancer, May 2023 (epub ahead of print)
JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response Tossoni L et al. Ann Hematol, May 2023
April 2023
The outcome of post-transplant asciminib in patients with CML Fernando F et al. Bone Marrow Transplant, April 2023 (epub ahead of print)	New patterns of genetic instability in chronic myelogenous leukemia: interesting, but not ready for clinical use Schiffer CA. Haematologica, April 2023 (epub ahead of print) – open access publion
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial Réa D et al. Leukemia, April 2023 (epub ahead of print) – open access publication	The structure of the hematopoietic system can explain chronic myeloid leukemia progression Pérez-Jiménez M et al. Sci Rep, April 2023 – open access publication
Management of chronic myeloid leukemia in 2023 – Common ground and common sense - Review Senapati J et al. Blood Cancer J, April 2023 – open access publication	Characterization of bone marrow niche in chronic myeloid leukemia patients identifies CXCL14 as a new therapeutic option Polinska M et al. Blood, April 2023 (epub ahead of print)
Efficacy and safety of nilotinib in chronic myeloid leukemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study Dulucq S et al. Br J Haematol, April 2023 (epub ahead of print) – open access publication	IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia Fiordi B et al. Haematologica, April 2023 (epub ahead of print) – open access publication
Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event Tarantini F et al. Leuk Res, April 2023	Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia Zhong FM et al. Cancer Cell Int, April 2023 – open access publication
Managing women of childbearing age with chronic myeloid leukemia: Safety and treatment considerations Expert Rev Hematol, April 2023 (epub ahead of print)	Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia Zhong FM et al. Cancer Cell Int, April 2023 – open access publication
An analysis of dasatinib treatment patterns in patients with chronic myeloid leukemia after experiencing pleural effusion during dasatinib therapy McBride A et al. Acta Haematol, April 2023 (epub ahead of print)
Efficacy and safety of nilotinib as frontline therapy in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials Luciano L et al. Ann Hematol, April 2023 (epub ahead of print) – open access publication
Applications of machine learning in chronic myeloid leukemia - Review Elhadary M et al. Diagnostics(Basel), April 2023 – open access publication
Breaking the mold: asciminib as a standard of care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting Yilmaz R et al. Future Oncol, April 2023 (epub ahead of print)
Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia – Review Han JJ et al. Blood Res, April 2023 (epub ahead of print) – open access publication
Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings - Review Cheng F et al. Front Oncol, April 2023 – open access publication
Assessment of imatinib as a primary treatment of chronic myeloid leukemia in chronic phase: a Cohort Study Merin D et al. J Oncol Pharm Pract, April 2023
March 2023
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL Hochhaus A et al. Leukemia, March 2023 – open access publication	AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells Lee YC et al. Biochem Pharmacol, March 2023
A sciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results Mauro MJ et al. Leukemia, March 2023 (epub ahead of print) – open access publication	The interplay between telomeric complex members and BCR::ABL1 oncogenic tyrosine kinase in the maintenance of telomere lengths in chronic myeloid leukemia Deregowska A et al. J Cancer Res Clin Oncol, March 2023 (epub ahead of print) – open access publication
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention Shanmunagathan N et al. Haematologica, March 2023 (epub ahead of print) – open access publication	Induction of DNMT1-dependent demethylation of SHP-1 by the natural flavonoid compound Baicalein overcame imatinib-resistance in CML CD34+ cells Xu X et al. Cell Commun Signal, March 2023 – open access publication
Editorial: Advances in the treatment of chronic myeloid leukemia Eskazan AE et al. Front Oncol, March 2023 – open access publication	Imatinib blocks tyrosine phosphorylation of Smad4 and restores TFG-ß growth-suppressive signaling in BCR-ABL1-positive leukemia Wang L et al. Signal Transduct Target Ther, March 2023 – open access publication
High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population Kockerols CCB et al. Haematologica, March 2023 (epub ahead of print) – open access publication	The prognostic and therapeutic potential of HO-1 in leukemia and MDS – Review Sadeghi M et al. Cell Commun Signal, March 2023 – open access publication
Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence Shallis RM et al. Blood Adv, March 2023 (epub ahead of print) – open access publication	NOX2 and NOX4 control mitochondrial function in chronic myeloid leukemia Romo-González M et al. Free Radic Biol Med, March 2023 – open access publication
The economic burden of chronic myeloid leukemia in patients with later lines: Findings from a real-world analysis in Italy Breccia M et al. Adv Ther, March 2023 – open access publication	TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN Qiu Q et al. Signal Transduct Target Ther, March 2023 – open access publication
A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia Krishnan V et al. Blood, March 2023 (epub ahead of print)	Molecular mechanisms of tyrosine kinase inhibitor resistance in chronic myeloid leukemia Kaehler M and Cascorti I. Handb Exp Pharmacol, March 2023 (epub ahead of print)
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian Medicines Agency (AIFA) Breccia M et al. Ann Hematol, March 2023 (epub ahead of print)
Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm Walia A and Prasad V. Blood Cancer J, March 2023 – open access publication
Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia Aleem A et al. Int J Hematol, March 2023 (epub ahead of print)
Association between bariatric surgery and outcomes in chronic myeloid leukemia Haddad FG et al. Cancer, March 2023 (epub ahead of print)
Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase – Review Choi EJ. Blood Res, March 2023 (epub ahead of print) – open access publication
Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia (RODEO study): study protocol for prospective, multicentre, single-arm trial Djodikromo MF et a. BMC Cancer, March 2023 – open access publication
February 2023
Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells Tsubaki M et al. BMB Rep, February 2023 – open access publication	Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for the novo lymphoid blast phase-chronic myeloid leukemia Yang Z et al. Leuk Res, February 2023 (epub ahead of print)
Repurposing the Bis-Biguanide Alexidine in combination with tyrosine kinase inhibitors to eliminate leukemic stem/progenitor cells in chronic myeloid leukemia Muselli F et al. Cancers(Basel), February 2023 – open access publication	Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: characteristics, potential mechanism, and clinical management strategies – Review Cheng F et al. Front Oncol, February 2023 – open access publication
Discovery of CZS-241: A potent, selective, and orally available Polo-like kinase 4 inhibitor for the treatment of CML Sun Y et al. J Med Chem, February 2023	Cardiovascular toxicities associated with tyrosine kinase inhibitors - Review Sahegh N et al. Curr Cardiol Rep, February 2023 (epub ahead of print)
Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia Jiang B et al. Front Oncol, February 2023 – open access publication	The bone marrow immune environment in CML: Treatment responses, treatment-free remission and therapeutic vulnerabilities Patterson SD & Copland M. Curr Hematol Malig Rep, February 2023 (epub ahead of print) – open access publication
A survey of patient experience in CML: American and Canadian Perspectives Hillis C et al. Patient Prefer Adherence, February 2023 – open access publication
Importance of tyrosine kinase inhibitor treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-Free study Yoshida C et al. Int J Hematol, February 2023 (epub ahead of print) – open access publication
Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network Nunes RAB et al. Front Cardiovasc Med, February 2023 – open access publication
Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison Hyland KA et al. Leuk Lymphoma, February 2023
Family planning and pregnancy in patients with chronic myeloid leukemia – Review Berman E et al. Curr Hematol Malig Rep, February 2023 (epub ahead of print)
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modelling and pathway analysis Radich JP et al. Haematologica, February 2023 (epub ahead of print) – open access publication
January 2023
Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in CML Irani YD et al. Blood Adv, January 2023 (epub ahead of print) – open access publication	Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL Hochhaus A et a. Leukemia, January 2023 (epub ahead of print) – open access publication
RHOA-regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia Zhang H et al. Haematologica, January 2023 – open access publication	Matching adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors Atallah E et al. J Caner Res Clin Oncol, January 2023 (epub ahead of print) – open access publication
Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib Häselbarth L et al. Cancer Immunol Immunother, January 2023 (epub ahead of print) – open access publication	Allogeneic transplantation for chronic myeloid leukemia: I’m not dead yet! Radich J. Am J Hematol, January 2023 – open access publication
mTORC2 is activated under hypoxia and could support chronic myeloid leukemia stem cells Panuzzo C et al. Int J Mol Sci, January 2023 – open access publication	Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor Bidikian A et al. Am J Hematol (epub ahead of print)
BH3 mimetics and TKI combined therapy for CML Brumatti G et al. Biochem, January 2023 – open access publication	The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors Jabbour EJ et al. Am J Hematol, January 2023 (epub ahead of print)
Differential inhibition of T cell receptor and STAT5 signalling pathways determine the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia Harrington P et al. Haematologica, January 2023 (epub ahead of print) – open access publication	A systematic review on second treatment-free remission (TFR) attempt in chronic myeloid leukemia (CML): Can it be applied in clinical practice? - Review Çiftçiler R et al. Clin Lymphoma Myeloma Leuk (epub ahead of print)
	Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring Bataller A et al. Leuk Lymphoma, January 2023 (epub ahead of print)
	Is it time to reconsider molecular response milestones in CML? Walia A and Prasad V. Am J Hematol, January 2023 (epub ahead of print)